Pancreatic Cancer Research

ResearcherThomas Jefferson UniversityActive in the last 2 years

Avinoam Nevler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5928-0559; OpenAlex author ID A5020033657. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 22

  1. Initial Site of Metastasis Influences Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/cam4.71760↗
  2. Preoperative Glucose-to-Albumin Ratio as a Prognostic Marker for Survival in Pancreatic Cancer Patients Undergoing Pancreatectomy. Last author DOI 10.1002/cam4.72256↗
  3. Survival Impact of Intraoperative Carbon Dioxide Dysregulation in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/xcs.0000000000001760↗
  4. Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/cam4.70960↗
  5. P53 Function Status Correlates With Overall Survival in Patients With Resected Pancreatic Cancer. Last author DOI 10.1002/jso.70060↗
  6. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  7. Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002458↗
  8. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. Last author DOI 10.3390/ijms26072848↗
  9. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm13072103↗
  10. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5858/arpa.2023-0005-oa↗
  11. Hypercapnic Tissue Gene Expression and Survival in Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000552↗
  12. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancrea… Last author DOI 10.1136/bmjopen-2023-073839↗
  13. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. Co-author DOI 10.1002/jso.26860↗
  14. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  15. The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Sali… Co-author DOI 10.1245/s10434-022-11978-3↗
  16. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  17. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Co-author DOI 10.1158/1541-7786.mcr-20-0985↗
  18. Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure. Co-author DOI 10.1007/s00520-019-05214-0↗
  19. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Co-author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  20. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  21. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Co-author DOI 10.1016/j.jamcollsurg.2017.12.052↗
  22. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-17-0015↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 21 shared papers, 2017–2026 · strength 3.93
  2. Harish Lavu · 16 shared papers, 2018–2026 · strength 3.41
  3. Aditi Jain · 10 shared papers, 2019–2025 · strength 1.91
  4. Wei Jiang · 6 shared papers, 2022–2025 · strength 1.16
  5. Jonathan Robert Brody · 9 shared papers, 2017–2025 · strength 1.05
  6. Andrea Feci · 2 shared papers, 2026 · strength 0.57
  7. Christopher William Schultz · 5 shared papers, 2019–2023 · strength 0.56
  8. Richard Zheng · 2 shared papers, 2025–2026 · strength 0.54
  9. Theresa Pluth Yeo · 4 shared papers, 2018–2023 · strength 0.48
  10. Faria Nusrat · 2 shared papers, 2024–2025 · strength 0.47
  11. Matthew McCoy · 3 shared papers, 2021–2025 · strength 0.45
  12. Michael Jon Pishvaian · 3 shared papers, 2019–2025 · strength 0.39
  13. Grace A. McCarthy · 4 shared papers, 2019–2022 · strength 0.39
  14. Eleanor Mancheski · 1 shared paper, 2026 · strength 0.36
  15. Rosalie C. Sears · 2 shared papers, 2022–2025 · strength 0.35
  16. Jordan Michael Winter · 4 shared papers, 2017–2020 · strength 0.33
  17. Samantha Z. Brown · 3 shared papers, 2020–2022 · strength 0.32
  18. Ashley Wetzel · 1 shared paper, 2026 · strength 0.29
  19. Nader N Hanna · 1 shared paper, 2026 · strength 0.29
  20. Talia Golan · 3 shared papers, 2019–2021 · strength 0.29
  21. Zachary Kaplan · 1 shared paper, 2025 · strength 0.28
  22. David O. Nauheim · 2 shared papers, 2020–2022 · strength 0.26
  23. Hui Chen · 1 shared paper, 2025 · strength 0.26
  24. Nitzan Zohar · 1 shared paper, 2025 · strength 0.26
  25. Sohum D. Patel · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.